Abstract
The recommendations of the German Society of Rheumatology (DGRh) update, which update and expand the guidance on the management of patients with inflammatory rheumatic diseases in view of SARS-CoV\hbox-2 created at the beginning of the COVID-19 pandemic, correspond in many points with the recommendations for action of the American (ACR) and European (EULAR) societies, but also differ in some points. Therefore, this article discusses the core recommendations of the DGRh update on the prevention of SARS-CoV-2/COVID-19, the risk assessment for inflammatory rheumatic diseases and the use of antirheumatic treatments in the context and in comparison to the ACR and EULAR recommendations, and provides an overview of the risk assessment of individual antirheumatic drugs.
Dokumententyp: | Zeitschriftenartikel |
---|---|
Publikationsform: | Publisher's Version |
Fakultät: | Medizin |
URN: | urn:nbn:de:bvb:19-epub-73484-8 |
Sprache: | Deutsch |
Dokumenten ID: | 73484 |
Datum der Veröffentlichung auf Open Access LMU: | 25. Sep. 2020, 12:18 |
Letzte Änderungen: | 04. Nov. 2020, 13:53 |